TY - JOUR
T1 - Von Willebrand Factor antigen and age explain variation in baseline FVIII:C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser)
AU - Loomans, Janneke I.
AU - Van Velzen, Alice S.
AU - Eckhardt, Corien L.
AU - Peters, Marjolein
AU - Astermark, Jan
AU - Brons, Paul P.
AU - Castaman, Giancarlo
AU - Cnossen, Marjon H.
AU - Dors, Natasja
AU - Escuriolaettingshausen, Carmen
AU - Hamulyak, Karly
AU - Hart, Daniel P.
AU - Hay, Charles R.M.
AU - Haya, Saturnino
AU - Van Heerde, Waander L.
AU - Hermans, Cedric
AU - Holmström, Margaretha
AU - Imenez-Yuste, Victor J.
AU - Keenan, Russell D.
AU - Klamroth, Robert
AU - Königs, Christoph
AU - Kruip, Marieke J.H.A.
AU - Laros-Van Gorkom, Britta A.P.
AU - Leebeek, Frank W. G.
AU - Liesner, Ri
AU - Mäkipernaa, Anne
AU - Male, Christoph
AU - Mauser-Bunschoten, Evelien
AU - Mazzucconi, Maria G.
AU - Mcrae, Simon
AU - Meijer, Karina
AU - Mitchell, Michael
AU - Morfini, Massimo
AU - Nijziel, Marten
AU - Oldenburg, Johannes
AU - Peerlinck, Kathelijne
AU - Petrini, Pia
AU - Platokouki, Helen
AU - Rangarajan, Savita
AU - Reitter-Pfoertner, Sylvia E.
AU - Santagostino, Elena
AU - Schinco, Piercarla
AU - Smiers, Frans J.
AU - Siegmund, Berthold
AU - Tagliaferri, Annarita
AU - Yee, Thynn T.
AU - Kamphuisen, Pieter Willem
AU - Van Der Bom, Johanna G.
AU - Fijnvandraat, Karin
PY - 2014/5/1
Y1 - 2014/5/1
N2 - Introduction and Objectives: Non-severe hemophilia A (baseline FVIII:C, 2-40 IU/dL) is caused by a mutation in the F8 gene. There is limited knowledge on the factors determining the variation in baseline FVIII:C. The aim is to identify the determinants of baseline FVIII:C in non-severe hemophilia A patients. Materials and Methods: We analyzed clinical data for non-severe hemophilia A patients, treated between 1980-2013, in European Haemophilia Treatment Centers (HTCs) participating in the INSIGHT/RISE project. We performed analyses on mutations that were present in ≥10 patients. Age (at FVIII:C measurement), F8 gene mutation, VWF:Ag, VWF:Act and HTC were analyzed as potential determinants by multivariate regression analyses. Results: We identified nine missense mutations present in ≥10 patients in 321 individuals, median age 23 years (IQR 7-47). From these individuals we had data on 667 FVIII:C measurements in 5 HTCs. Median baseline FVIII:C, VWF:Ag and VWF: Act were 17 IU/dL (IQR 11-22), 98 IU/dL (IQR 78-128) and 91 IU/dL (70-115) respectively. Baseline FVIII:C, VWF:Ag and VWF:Act all increased with age, both in the total population and within the two largest mutation groups (Asn618Ser, 113 patients; Arg593Cys, 107 patients). VWF:Ag, age and F8 mutation were significant predictors of baseline FVIII:C (p <0.0001-0.024). In mutations that were present in ≥10 patients the determinants age, F8 mutation, VWF:Ag and HTC together explained 61% of the variation in baseline FVIII:C. Within the specific mutation group Asn618Ser only 21% of the variance in baseline FVIII:C was explained by the combined potential determinants, with VWF:Ag and HTC as significant predictors (p = 0.008 and 0.013 respectively). Among individuals with the Arg593Cys F8 genotype the determinants age, VWF:Ag and HTC were significant predictors (p <0.0001 for age and VWF:Ag and p = 0.04 for HTC), together explaining 34% of the variance in baseline FVIII:C. Conclusion: In non-severe hemophilia A patients carrying the same F8 mutation the determinants age, VWF:Ag and HTC contribute to baseline FVIII:C to variable extends. With the studied determinants we can only explain 61% of the variance in baseline FVIII:C. This suggests that yet unknown factors influence FVIII:C in nonsevere hemophilia A.
AB - Introduction and Objectives: Non-severe hemophilia A (baseline FVIII:C, 2-40 IU/dL) is caused by a mutation in the F8 gene. There is limited knowledge on the factors determining the variation in baseline FVIII:C. The aim is to identify the determinants of baseline FVIII:C in non-severe hemophilia A patients. Materials and Methods: We analyzed clinical data for non-severe hemophilia A patients, treated between 1980-2013, in European Haemophilia Treatment Centers (HTCs) participating in the INSIGHT/RISE project. We performed analyses on mutations that were present in ≥10 patients. Age (at FVIII:C measurement), F8 gene mutation, VWF:Ag, VWF:Act and HTC were analyzed as potential determinants by multivariate regression analyses. Results: We identified nine missense mutations present in ≥10 patients in 321 individuals, median age 23 years (IQR 7-47). From these individuals we had data on 667 FVIII:C measurements in 5 HTCs. Median baseline FVIII:C, VWF:Ag and VWF: Act were 17 IU/dL (IQR 11-22), 98 IU/dL (IQR 78-128) and 91 IU/dL (70-115) respectively. Baseline FVIII:C, VWF:Ag and VWF:Act all increased with age, both in the total population and within the two largest mutation groups (Asn618Ser, 113 patients; Arg593Cys, 107 patients). VWF:Ag, age and F8 mutation were significant predictors of baseline FVIII:C (p <0.0001-0.024). In mutations that were present in ≥10 patients the determinants age, F8 mutation, VWF:Ag and HTC together explained 61% of the variation in baseline FVIII:C. Within the specific mutation group Asn618Ser only 21% of the variance in baseline FVIII:C was explained by the combined potential determinants, with VWF:Ag and HTC as significant predictors (p = 0.008 and 0.013 respectively). Among individuals with the Arg593Cys F8 genotype the determinants age, VWF:Ag and HTC were significant predictors (p <0.0001 for age and VWF:Ag and p = 0.04 for HTC), together explaining 34% of the variance in baseline FVIII:C. Conclusion: In non-severe hemophilia A patients carrying the same F8 mutation the determinants age, VWF:Ag and HTC contribute to baseline FVIII:C to variable extends. With the studied determinants we can only explain 61% of the variance in baseline FVIII:C. This suggests that yet unknown factors influence FVIII:C in nonsevere hemophilia A.
KW - von Willebrand factor
KW - antigen
KW - silver
KW - hemophilia A
KW - patient
KW - human
KW - genotype
KW - hemophilia
KW - mutation
KW - missense mutation
KW - regression analysis
KW - gene mutation
KW - population
KW - clinical study
KW - gene
M3 - Meeting Abstract
VL - 20
SP - 56
JO - Haemophilia
JF - Haemophilia
SN - 1351-8216
ER -